Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1080-44-0

Post Buying Request

1080-44-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1080-44-0 Usage

Uses

N-Tosylglycine is a sulfonamide derivative used to synthesize metal complexes which potentially displays antibacterial activity.

Check Digit Verification of cas no

The CAS Registry Mumber 1080-44-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,0,8 and 0 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1080-44:
(6*1)+(5*0)+(4*8)+(3*0)+(2*4)+(1*4)=50
50 % 10 = 0
So 1080-44-0 is a valid CAS Registry Number.
InChI:InChI=1/C9H11NO4S/c1-7-2-4-8(5-3-7)15(13,14)10-6-9(11)12/h2-5,10H,6H2,1H3,(H,11,12)

1080-44-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (T2803)  N-(p-Toluenesulfonyl)glycine  >98.0%(HPLC)(T)

  • 1080-44-0

  • 5g

  • 290.00CNY

  • Detail
  • TCI America

  • (T2803)  N-(p-Toluenesulfonyl)glycine  >98.0%(HPLC)(T)

  • 1080-44-0

  • 25g

  • 980.00CNY

  • Detail
  • Alfa Aesar

  • (H53371)  N-(p-Toluenesulfonyl)glycine, 97%   

  • 1080-44-0

  • 5g

  • 279.0CNY

  • Detail
  • Alfa Aesar

  • (H53371)  N-(p-Toluenesulfonyl)glycine, 97%   

  • 1080-44-0

  • 25g

  • 1117.0CNY

  • Detail
  • Aldrich

  • (403458)  N-p-Tosylglycine  97%

  • 1080-44-0

  • 403458-1G

  • 168.48CNY

  • Detail

1080-44-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name N-p-Tosylglycine

1.2 Other means of identification

Product number -
Other names 2-(4-Methylphenylsulfonamido)acetic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1080-44-0 SDS

1080-44-0Synthetic route

p-toluenesulfonyl chloride
98-59-9

p-toluenesulfonyl chloride

glycine
56-40-6

glycine

N-Tosylglycine
1080-44-0

N-Tosylglycine

Conditions
ConditionsYield
With sodium carbonate In water for 5h;99.34%
With sodium carbonate In water for 4h;99.34%
With triethylamine In tetrahydrofuran; water at 0 - 20℃; for 4h; Inert atmosphere;94%
sodium p-methylbenzoate
17264-54-9

sodium p-methylbenzoate

glycine
56-40-6

glycine

N-Tosylglycine
1080-44-0

N-Tosylglycine

Conditions
ConditionsYield
With lithium perchlorate In water; acetonitrile for 1h; Electrochemical reaction;48%
toluene-4-sulfonamide
70-55-3

toluene-4-sulfonamide

chloroacetic acid
79-11-8

chloroacetic acid

N-Tosylglycine
1080-44-0

N-Tosylglycine

Conditions
ConditionsYield
With sodium hydroxide
With sodium hydroxide
2-aminoethanoic acid hydrochloride
6000-43-7

2-aminoethanoic acid hydrochloride

p-toluenesulfonyl chloride
98-59-9

p-toluenesulfonyl chloride

N-Tosylglycine
1080-44-0

N-Tosylglycine

Conditions
ConditionsYield
With potassium hydroxide
Stage #1: 2-aminoethanoic acid hydrochloride With sodium hydroxide In water pH=9;
Stage #2: p-toluenesulfonyl chloride In water at 25℃; for 4h;
p-toluenesulfonyl chloride
98-59-9

p-toluenesulfonyl chloride

glycine
56-40-6

glycine

A

1,4-bis[(4-methylphenyl)sulfonyl]tetrahydropyrazine-2,5-dione
95021-64-0

1,4-bis[(4-methylphenyl)sulfonyl]tetrahydropyrazine-2,5-dione

B

N-Tosylglycine
1080-44-0

N-Tosylglycine

Conditions
ConditionsYield
With potassium hydroxide
N-tosylimidazole
2232-08-8

N-tosylimidazole

glycine
56-40-6

glycine

A

1H-imidazole
288-32-4

1H-imidazole

B

N-Tosylglycine
1080-44-0

N-Tosylglycine

Conditions
ConditionsYield
With hydrogenchloride; tetramethlyammonium chloride In ethanol at 25℃; Rate constant; μ=0.16 M;
1-tosyl-3-methyl-imidazolium chloride
29981-92-8

1-tosyl-3-methyl-imidazolium chloride

glycine
56-40-6

glycine

N-Tosylglycine
1080-44-0

N-Tosylglycine

Conditions
ConditionsYield
In ethanol; water
1-tosyl-3-methyl-imidazolium chloride
29981-92-8

1-tosyl-3-methyl-imidazolium chloride

glycine
56-40-6

glycine

A

N-Tosylglycine
1080-44-0

N-Tosylglycine

B

1-methylimidazolium chloride
35487-17-3

1-methylimidazolium chloride

Conditions
ConditionsYield
With hydrogenchloride; tetramethlyammonium chloride In ethanol at 25℃; Rate constant; μ=0.16 M;
1-tosyl-2,3-dimethylimidazolium chloride
51060-12-9

1-tosyl-2,3-dimethylimidazolium chloride

glycine
56-40-6

glycine

A

N-Tosylglycine
1080-44-0

N-Tosylglycine

B

2,3-dimethylimidazolium chloride
34531-53-8

2,3-dimethylimidazolium chloride

Conditions
ConditionsYield
With hydrogenchloride; tetramethlyammonium chloride In ethanol at 25℃; Rate constant; μ=0.16 M;
N-nitroso-N-(4-toluenesulfonyl)-glycine
98953-60-7

N-nitroso-N-(4-toluenesulfonyl)-glycine

water
7732-18-5

water

N-Tosylglycine
1080-44-0

N-Tosylglycine

TsGlyNHMe
115901-56-9

TsGlyNHMe

A

N-Tosylglycine
1080-44-0

N-Tosylglycine

B

toluene-4-sulfonic acid
104-15-4

toluene-4-sulfonic acid

C

glycine methylamide
22356-89-4

glycine methylamide

D

2-oxopropanal
78-98-8

2-oxopropanal

Conditions
ConditionsYield
With water In acetonitrile Photolysis; Further byproducts.;
methyl tosylglycinate
2645-02-5

methyl tosylglycinate

N-Tosylglycine
1080-44-0

N-Tosylglycine

Conditions
ConditionsYield
With lithium hydroxide monohydrate In tetrahydrofuran; methanol at 20℃; for 2h;
p-toluenesulfonyl chloride
98-59-9

p-toluenesulfonyl chloride

N-Tosylglycine
1080-44-0

N-Tosylglycine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N-ethyl-N,N-diisopropylamine / dichloromethane / 16 h / 0 - 20 °C
2: lithium hydroxide monohydrate / tetrahydrofuran; methanol / 2 h / 20 °C
View Scheme
methanol
67-56-1

methanol

N-Tosylglycine
1080-44-0

N-Tosylglycine

methyl tosylglycinate
2645-02-5

methyl tosylglycinate

Conditions
ConditionsYield
With sulfuric acid Reflux;100%
With sulfuric acid at 20℃; for 3h;98%
With tert.-butylnitrite at 40℃; for 48h; Green chemistry;85%
N-Tosylglycine
1080-44-0

N-Tosylglycine

2-(4-methylphenylsulfonamido)acetyl chloride
56218-62-3

2-(4-methylphenylsulfonamido)acetyl chloride

Conditions
ConditionsYield
With thionyl chloride for 1.5h; Heating / reflux;100%
With diethyl ether; phosphorus pentachloride
With thionyl chloride at 45 - 50℃;
N-Tosylglycine
1080-44-0

N-Tosylglycine

allyl alcohol
107-18-6

allyl alcohol

allyl 2-(4-methylphenylsulfonamido)acetate

allyl 2-(4-methylphenylsulfonamido)acetate

Conditions
ConditionsYield
With toluene-4-sulfonic acid In benzene for 4h; Heating;99%
N-Tosylglycine
1080-44-0

N-Tosylglycine

benzoyl chloride
98-88-4

benzoyl chloride

{benzoyl[(4-methylphenyl)sulfonyl]amino}acetic acid

{benzoyl[(4-methylphenyl)sulfonyl]amino}acetic acid

Conditions
ConditionsYield
With sodium hydroxide at 20℃;98.49%
With sodium hydroxide at 20℃;98.49%
With sodium hydroxide at 20℃; for 2h; Inert atmosphere;
With sodium hydroxide at 20℃;
bis((μ-chloro)chloro(pentamethylcyclopentadienyl)iridium)

bis((μ-chloro)chloro(pentamethylcyclopentadienyl)iridium)

N-Tosylglycine
1080-44-0

N-Tosylglycine

C2H2NIrO(O)(C5(CH3)5)(SO2C6H4CH3)
157699-57-5

C2H2NIrO(O)(C5(CH3)5)(SO2C6H4CH3)

Conditions
ConditionsYield
With K2CO3 In acetonitrile N2-atmosphere, 5 h; concg., extg. (CH2Cl2), filtering, washing (CH2Cl2), concg., drying (vac.); elem. anal.;97%
C16H15BrN2

C16H15BrN2

N-Tosylglycine
1080-44-0

N-Tosylglycine

N-(2-(2-bromophenyl)-2-(1H-indol-3-yl)ethyl)-2-((4-methylphenyl)sulfonylamino)acetamide

N-(2-(2-bromophenyl)-2-(1H-indol-3-yl)ethyl)-2-((4-methylphenyl)sulfonylamino)acetamide

Conditions
ConditionsYield
With dmap; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 20℃; Inert atmosphere;90.8%
C17H15N3

C17H15N3

N-Tosylglycine
1080-44-0

N-Tosylglycine

N-(2-(4-cyanophenyl)-2-(1H-indol-3-yl)ethyl)-2-((4-methylphenyl)sulfonylamino)acetamide

N-(2-(4-cyanophenyl)-2-(1H-indol-3-yl)ethyl)-2-((4-methylphenyl)sulfonylamino)acetamide

Conditions
ConditionsYield
With dmap; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 20℃; Inert atmosphere;90.5%
N-Tosylglycine
1080-44-0

N-Tosylglycine

O-ethylphosphoric acid bis(3,5-dimethyl)pyrazolide
87023-83-4

O-ethylphosphoric acid bis(3,5-dimethyl)pyrazolide

Tos-Gly-DMPir
57891-04-0

Tos-Gly-DMPir

Conditions
ConditionsYield
In pyridine Ambient temperature;90%
N-Tosylglycine
1080-44-0

N-Tosylglycine

methyl 1-imidazolecarboxylate
61985-23-7

methyl 1-imidazolecarboxylate

methyl tosylglycinate
2645-02-5

methyl tosylglycinate

Conditions
ConditionsYield
In acetonitrile at 80℃; for 24h; Inert atmosphere; chemoselective reaction;90%
Chloro(chloromethyl)dimethylsilane
1719-57-9

Chloro(chloromethyl)dimethylsilane

N-Tosylglycine
1080-44-0

N-Tosylglycine

2,2,4-trimethyl-1-tosyl-2-sila-5-piperazinone
1448453-33-5

2,2,4-trimethyl-1-tosyl-2-sila-5-piperazinone

Conditions
ConditionsYield
With 1,1,1,3,3,3-hexamethyl-disilazane90%
N-Tosylglycine
1080-44-0

N-Tosylglycine

2,3-dimethyl-buta-1,3-diene
513-81-5

2,3-dimethyl-buta-1,3-diene

6-methyl-6-(prop-1-en-2-yl)-4-tosylmorpholin-2-one

6-methyl-6-(prop-1-en-2-yl)-4-tosylmorpholin-2-one

Conditions
ConditionsYield
Stage #1: N-Tosylglycine With copper diacetate; palladium diacetate In dimethyl sulfoxide at 20℃; for 0.25h; Autoclave;
Stage #2: 2,3-dimethyl-buta-1,3-diene With oxygen In dimethyl sulfoxide at 75℃; under 3800.26 Torr; for 24h; Autoclave;
90%
2-(1H-pyrrol-1-yl)aniline
6025-60-1

2-(1H-pyrrol-1-yl)aniline

N-Tosylglycine
1080-44-0

N-Tosylglycine

4-(tosylaminomethyl)pyrrolo[1,2-a]quinoxaline

4-(tosylaminomethyl)pyrrolo[1,2-a]quinoxaline

Conditions
ConditionsYield
With 1,2,2,3,4,4-hexamethylphosphetane 1-oxide; phenylsilane; Diethyl 2-bromomalonate In 1,2-dichloro-ethane at 80℃; for 14h; Sealed tube; Inert atmosphere;90%
N-Tosylglycine
1080-44-0

N-Tosylglycine

aniline
62-53-3

aniline

2-[[(4-methylphenyl)sulfonyl]amino]-N-phenylacetamide
2478-44-6

2-[[(4-methylphenyl)sulfonyl]amino]-N-phenylacetamide

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 0℃;89%
Stage #1: N-Tosylglycine With thionyl chloride In dichloromethane at 50℃; for 6h; Inert atmosphere;
Stage #2: aniline In tetrahydrofuran at 20℃; Inert atmosphere;
80%
(i) Py, tBuCOCl, (ii) /BRN= 605631/; Multistep reaction;
triethylene glucol monomethyl ether
112-35-6

triethylene glucol monomethyl ether

N-Tosylglycine
1080-44-0

N-Tosylglycine

2-(2-(2-methoxyethoxy)ethoxy)ethyl 2-(4-methylphenylsulfonamido)acetate
1224367-52-5

2-(2-(2-methoxyethoxy)ethoxy)ethyl 2-(4-methylphenylsulfonamido)acetate

Conditions
ConditionsYield
With toluene-4-sulfonic acid In 5,5-dimethyl-1,3-cyclohexadiene for 7h; Inert atmosphere; Reflux;89%
ethanol
64-17-5

ethanol

N-Tosylglycine
1080-44-0

N-Tosylglycine

ethyl N-tosylglycinate
5465-67-8

ethyl N-tosylglycinate

Conditions
ConditionsYield
With sulfuric acid Reflux;88%
With sulfuric acid for 4h; Heating;75%
With sulfuric acid In toluene for 5h; Heating;69%
With hydrogenchloride
S-benzyl-L-cysteine methyl ester hydrochloride
16741-80-3

S-benzyl-L-cysteine methyl ester hydrochloride

N-Tosylglycine
1080-44-0

N-Tosylglycine

Tos-Gly-L-Cys(Bzl)-OMe

Tos-Gly-L-Cys(Bzl)-OMe

Conditions
ConditionsYield
With triethylamine; dicyclohexyl-carbodiimide In tetrahydrofuran at -5 - 20℃; for 50h;86%
N-Tosylglycine
1080-44-0

N-Tosylglycine

benzyl alcohol
100-51-6

benzyl alcohol

(toluene-4-sulfonylamino)acetic acid benzyl ester
63366-76-7

(toluene-4-sulfonylamino)acetic acid benzyl ester

Conditions
ConditionsYield
With toluene-4-sulfonic acid In toluene for 3h; Heating;86%
With sulfuryl dichloride In 1,1,2,2-tetrachloroethylene
N-Tosylglycine
1080-44-0

N-Tosylglycine

propargyl alcohol
107-19-7

propargyl alcohol

prop-2-ynyl 2-(4-methylphenylsulfonamido)acetate
1007362-49-3

prop-2-ynyl 2-(4-methylphenylsulfonamido)acetate

Conditions
ConditionsYield
With toluene-4-sulfonic acid In benzene for 4h; Heating;86%
N-Tosylglycine
1080-44-0

N-Tosylglycine

allylmagnesium bromide
1730-25-2

allylmagnesium bromide

N-(2-hydroxypent-4-enyl)-4-methylbenzenesulfonamide
1214887-93-0

N-(2-hydroxypent-4-enyl)-4-methylbenzenesulfonamide

Conditions
ConditionsYield
Stage #1: N-Tosylglycine With n-butyllithium In tetrahydrofuran; hexane at -78℃;
Stage #2: allylmagnesium bromide In tetrahydrofuran; diethyl ether; hexane at -78 - 20℃; for 2h; Further stages;
86%
N-Tosylglycine
1080-44-0

N-Tosylglycine

1-butyn-4-ol
927-74-2

1-butyn-4-ol

but-3-ynyl 2-(4-methylphenylsulfonamido)acetate

but-3-ynyl 2-(4-methylphenylsulfonamido)acetate

Conditions
ConditionsYield
With toluene-4-sulfonic acid In benzene for 4.5h; Heating;84%
Allylbenzylamine
4383-22-6

Allylbenzylamine

N-Tosylglycine
1080-44-0

N-Tosylglycine

N-allyl-N-benzyl-2-((4-methylphenyl)sulfonamido)acetamide

N-allyl-N-benzyl-2-((4-methylphenyl)sulfonamido)acetamide

Conditions
ConditionsYield
With 1-hydroxy-7-aza-benzotriazole; N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; Inert atmosphere;84%
Stage #1: N-Tosylglycine With thionyl chloride for 2h; Reflux;
Stage #2: Allylbenzylamine In dichloromethane at 20℃;
73%
Stage #1: N-Tosylglycine With thionyl chloride for 2h; Inert atmosphere; Reflux;
Stage #2: Allylbenzylamine In dichloromethane at 20℃; Inert atmosphere;
73%
benzyl 2-(benzyloxy)-4-((4-cyclohexylbenzyl)amino)benzoate
1241833-16-8

benzyl 2-(benzyloxy)-4-((4-cyclohexylbenzyl)amino)benzoate

N-Tosylglycine
1080-44-0

N-Tosylglycine

benzyl 2-(benzyloxy)-4-(N-(4-cyclohexylbenzyl)-2-((4-methylphenyl)sulfonamido)acetamido)benzoate
1331747-40-0

benzyl 2-(benzyloxy)-4-(N-(4-cyclohexylbenzyl)-2-((4-methylphenyl)sulfonamido)acetamido)benzoate

Conditions
ConditionsYield
Stage #1: N-Tosylglycine With dichlorotriphenylphosphorane In chloroform at 20℃; for 0.25h;
Stage #2: benzyl 2-(benzyloxy)-4-(4-cyclohexylbenzylamino)benzoate In chloroform at 100℃; for 0.5h; Irradiation;
84%
N-Tosylglycine
1080-44-0

N-Tosylglycine

2,4-Xylidine
95-68-1

2,4-Xylidine

N-(2,4-dimethylphenyl)-2-(4-methylphenylsulfonamido)acetamide

N-(2,4-dimethylphenyl)-2-(4-methylphenylsulfonamido)acetamide

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 0℃;83%
1-methylbuta-1,3-diene
2004-70-8

1-methylbuta-1,3-diene

N-Tosylglycine
1080-44-0

N-Tosylglycine

5-methyl-4-tosyl-6-vinylmorpholin-2-one

5-methyl-4-tosyl-6-vinylmorpholin-2-one

Conditions
ConditionsYield
Stage #1: N-Tosylglycine With copper diacetate; palladium diacetate In dimethyl sulfoxide at 20℃; for 0.25h; Autoclave;
Stage #2: 1-methylbuta-1,3-diene With oxygen In dimethyl sulfoxide at 75℃; under 3800.26 Torr; for 24h; Autoclave;
83%
N-Tosylglycine
1080-44-0

N-Tosylglycine

4-benzylamino-6-(5,5-dioxodibenzothiophen-2-yl)-2,3,4,5-tetrahydropyridazin-3-one
479480-27-8

4-benzylamino-6-(5,5-dioxodibenzothiophen-2-yl)-2,3,4,5-tetrahydropyridazin-3-one

(toluene-4-sulfonylamino)-acetic acid 4-benzylamino-6-(5,5-dioxo-5H-5λ6-dibenzothiophen-2-yl)-4,5-dihydro-pyridazin-3-yl ester

(toluene-4-sulfonylamino)-acetic acid 4-benzylamino-6-(5,5-dioxo-5H-5λ6-dibenzothiophen-2-yl)-4,5-dihydro-pyridazin-3-yl ester

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In tetrahydrofuran at 0 - 20℃; for 50h;81%
N-Tosylglycine
1080-44-0

N-Tosylglycine

diallylamine
124-02-7

diallylamine

N,N-diallyl-2-(4-methylphenylsulfonylamino)acetamide

N,N-diallyl-2-(4-methylphenylsulfonylamino)acetamide

Conditions
ConditionsYield
Stage #1: N-Tosylglycine With thionyl chloride for 2h; Reflux;
Stage #2: diallylamine In dichloromethane at 20℃;
81%
N-Tosylglycine
1080-44-0

N-Tosylglycine

Thiocarbohydrazide
2231-57-4

Thiocarbohydrazide

(4-amino-5-mercapto-s-triazol-3-yl)-methyl-4-tolylsulfonamide

(4-amino-5-mercapto-s-triazol-3-yl)-methyl-4-tolylsulfonamide

Conditions
ConditionsYield
at 180℃; for 0.25h;80%
N-Tosylglycine
1080-44-0

N-Tosylglycine

2-amino-4,6-di-tertbutylphenol
1643-39-6

2-amino-4,6-di-tertbutylphenol

N-(p-toluenesulfonyl)-glycine-3,5-di-tert-butyl-2-phenolamide

N-(p-toluenesulfonyl)-glycine-3,5-di-tert-butyl-2-phenolamide

Conditions
ConditionsYield
Stage #1: N-Tosylglycine With thionyl chloride at 20℃;
Stage #2: 2-amino-4,6-di-tertbutylphenol In tetrahydrofuran
80%
N-Tosylglycine
1080-44-0

N-Tosylglycine

benzene
71-43-2

benzene

Diphenylmethane
101-81-5

Diphenylmethane

Conditions
ConditionsYield
With sulfuric acid at 60 - 70℃;79%

1080-44-0Relevant articles and documents

In vitro aldose reductase inhibitory activity of substituted N-benzenesulfonylglycine derivatives

DeRuiter,Brubaker,Garner,Barksdale,Mayfield

, p. 149 - 152 (1987)

-

New carboxamide derivatives bearing benzenesulphonamide as a selective COX-II inhibitor: Design, synthesis and structure-activity relationship

Ugwu, David Izuchukwu,Okoro, Uchechukwu Chris,Ahmad, Hilal

, (2017)

Sixteen new carboxamide derivatives bearing substituted benzenesulphonamide moiety (7a-p) were synthesized by boric acid mediated amidation of appropriate benzenesulphonamide with 2-amino-4-picoline and tested for anti-inflammatory activity. One compound 7c showed more potent anti-inflammatory activity than celecoxib at 3 h in carrageenan-induced rat paw edema bioassay. Compounds 7g and 7k also showed good anti-inflammatory activity comparable to celecoxib. Compound 7c appeared selectivity index (COX-2/COX-1) better than celecoxib. Compound 7k appeared selectivity index (COX-2/COX-1) a little higher than the half of celecoxib while compound 7g is non-selective for COX-2. The LD50 of compounds 7c, 7g and 7k were comparable to celecoxib.

Novel Phenoxazinones as potent agonist of PPAR-α: Design, synthesis, molecular docking and in vivo studies

Ugwu, David I.,Okoro, Uchechukwu C.,Mishra, Narendra K.,Okafor, Sunday N.

, (2018)

Background: The use of statin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for the treatment of dyslipidemia has been associated with dose limiting hepatoxicity, mytotoxicity and tolerability due to myalgias thereby necessitating the synthesis of new drug candidates for the treatment of lipid disorder. Methods: The reaction of appropriate benzenesulphonamide with substituted phenoxazinone in the presence of phenylboronic acid gave the targeted compounds. The molecular docking study were carried out using autodock tool against peroxisome proliferator activated receptor alpha. The in vivo lipid profile were assayed using conventional methods. The kidney and liver function test were carried out to assess the effect of the derivatives on the organs. The LD50 of the most active derivatives were determined using mice. Results: The targeted compounds were successfully synthesized in excellent yields and characterized using spectroscopic techniques. The results of the molecular docking experiment showed that they were good stimulant of peroxisome proliferator activated receptor alpha. Compound 9f showed activity at Ki of 2.8 nM and binding energy of 12.6 kcal/mol. All the compounds tested reduced triglyceride, total cholesterol, low density lipoprotein cholesterol and very low density lipoprotein cholesterol level in the mice model. Some of the reported compounds also increased high density lipoprotein cholesterol level in the mice. The compounds did not have appreciable effect on the kidney and liver of the mice used. The LD50 showed that the novel compounds have improved toxicity profile. Conclusion: The synthesis of fifteen new derivatives of carboxamides bearing phenoxazinone and sulphonamide were successful. The compounds possessed comparable activity to gemfibrozil. The reported compounds had better toxicity profile than gemfibrozil and could serve as a replacement for the statins and fibrate class of lipid agents.

Synthesis, characterization, and cytotoxicity of mixed-ligand complexes of platinum(II) with 2,2′-bipyridine and 4-toluenesulfonyl-L-amino acid dianion

Zhang, Jin Chao,Li, Luwei,Ma, Lili,Zhang, Fangfang,Wang, Shuxiang

, p. 1695 - 1706 (2011)

Five new platinum(II) complexes (1-5) with 4-toluenesulfonyl-L-amino acid dianion and 2,2′-bipyridine (bipy) have been synthesized and characterized by elemental analysis, IR, UV, 1H-NMR, 13C-NMR, and mass spectra. The crystal structure of 1 has been determined by X-ray diffraction analysis. Cytotoxicity was tested by 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) and sulforhodamine B (SRB) assays. The results indicate that 1-5 exert cytotoxic effects with selectivity against tested carcinoma cell lines; 5 displays better cytotoxicity against BGC-823, Bel-7402, and KB cell lines, while 1 has better cytotoxicity against KB cell line. The 4-toluenesulfonyl- L-amino acid dianions have important effects on cytotoxicity; when 4-toluenesulfonyl-L-amino acid dianions are 4-toluenesulfonyl-L-glycine and 4-toluenesulfonyl-L-phenylalanine, the complexes show better cytotoxicity.

Synthesis, characterization, and cytotoxicity of complexes of palladium(II) with 1,4-diaminobutane/1,3-diaminopropane and 4-toluenesulfonyl-L-amino acid dianion

Ma, Lili,Zhang, Jinchao,Zhang, Fangfang,Chen, Chao,Li, Luwei,Wang, Shuxiang,Li, Shenghui

, p. 3160 - 3173 (2012)

Eight new palladium(II) complexes with 4-toluenesulfonyl-L-amino acid dianion and 1,4-dab/1,3-dap, [Pd(1,4-dab)(TsglyNO)]H2O (1), [Pd(1,4-dab)(TsvalNO)] (2), [Pd(1,4-dab)(TsleuNO)] (3), [Pd(1,4-dab)(TsileNO)] (4), [Pd(1,4-dab)(TsserNO)]0.5H2O (5), [Pd(1,4-dab)(TspheNO)]0. 5H2O (6), [Pd(1,4-dab)(TsthrNO)]H2O (7), and [Pd(1,3-dap)(TsserNO)] (8), have been synthesized and characterized by elemental analysis, IR, UV, 1H NMR, and mass spectrometry. Crystal structure of 8 has been determined by X-ray diffraction. The cytotoxicities were tested by MTT assay. The results indicate the complexes exert cytotoxic effects against HL-60 and Bel-7402. The structure-activity relationship suggests that both amino acids and N-containing ligands have important effects on cytotoxicity, but the IC50 values do not show definite correlation with variation of these ligands.

Inducing Endoplasmic Reticulum Stress to Expose Immunogens: A DNA Tetrahedron Nanoregulator for Enhanced Immunotherapy

Li, Yanhua,Zhang, Xia,Wan, Xiuyan,Liu, Xiaohan,Pan, Wei,Li, Na,Tang, Bo

, (2020)

Immunogenic cell death (ICD) is an important modulation type for stimulating anticancer immune responses and amplifying immunotherapy efficacy. When ICD occurs, endoplasmic reticulum (ER) stress plays a vital role for exposing immunogens. Herein, a functionalized DNA tetrahedron nanoregulator to specifically trigger ER stress for enhancing cancer immunotherapy is designed. The nanoregulator can target ER organelles by binding to the sulfonamide receptor of cancer cells. Then glucose depletion and reactive oxygen species generation cause a strong ER stress response to induce ICD to expose tumor immunogens. Thereafter, the dendritic cell (DC) maturation is promoted, and T cell proliferation and infiltration are stimulated to advance cancer immunotherapy. Combined with immune checkpoint inhibitor (α-PD-1), the ER stress triggered nanoregulator exhibits significant suppression for breast cancer and melanoma.

IMPROVED PROCESS FOR THE PREPARATION OF ROXADUSTAT

-

Page/Page column 18; 23, (2021/10/30)

A synthetic route for the preparation of Roxadustat, or a pharmaceutically acceptable salt thereof. Each route involves several novel intermediates and avoids the use of column chromatography.

Intramolecular Aminoazidation of Unactivated Terminal Alkenes by Palladium-Catalyzed Reactions with Hydrogen Peroxide as the Oxidant

Beccalli, Egle M.,Broggini, Gianluigi,Foschi, Francesca,Lo Presti, Leonardo,Loro, Camilla,Oble, Julie,Poli, Giovanni,Sala, Roberto

supporting information, (2020/02/28)

The palladium-catalyzed aminoazidation of aminoalkenes yielding azidomethyl-substituted nitrogen-containing heterocycles was developed. The procedure requires oxidative conditions and occurs at room temperature in the presence of hydrogen peroxide and NaN3 as the azide source. These conditions provide selective exo-cyclization/azidation of the carbon-carbon double bond, furnishing a versatile approach toward five-, six-, and seven-membered heterocyclic rings.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1080-44-0